<p><span style="color: black; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; font-size: 11pt; mso-fareast-font-family: Calibri; mso-themecolor: text1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">Employers look for professionals able to work in a team, able to approach the problems, with the capacity to analyze and resolve problems, under the constant renewal of knowledge and competencies. In this paper, a group of University teachers from different areas of knowledge presents an experience to introduce key employability skills in the higher education students’ curricula. This work has been developed under the action research scope. The first goal was to make an analysis of terms referred to key skills, generating an integrated denomination for each competency. The elaboration of general templates for key skills is proposed here as a useful tool that provides information about development, assessment and marking of each skill. Different types of rubrics and assessment templates, used during this experience, are presented.</span></p>

No abstract

No abstract

BackgroundUveitis is a frequent extraarticular manifestation of spondyloarthritis (SpAs). It has been classically reported that whereas uveitis in axial spondyloarthritis (ax-SpA) is predominantly anterior, unilateral, acute, and non-recurrent; in psoriatic arthritis (PsA) and in inflammatory bowel disease (IBD) it has been described as posterior, bilateral, insidious, and continuous [1,2].ObjectivesIn a large unselected series of SpAs, our aim was to assess the epidemiology and clinical features of SpAs-associated uveitis.MethodsStudy of consecutive patients from a single University Hospital with a) ax-SpA, b) PsA, and c) IBD (Crohn’s disease and Ulcerative colitis). We have selected patients with uveitis that were classified according to Standarization Uveitis Nomenclature (SUN) Working Group. Main general features, and uveitis pattern, location and onset were recorded.ResultsWe studied 2156 (1038 women/118 men) patients with SpAs: IBD (n= 1449; 67.2%); PsA (n= 406; 18.8%); and ax-SpA (n= 301; 14%).Uveitis was present in 87 (4%) (102 eyes) of 2156 patients with SpAs. However, uveitis occurs with varying frequency according to the SpAs subtype:14.6% of axSpA (n=44), 4.9% of PsA (n=20), and 1.6% of IBD (n=23) (Table 1).In the global SpAs, the most common pattern of uveitis was typically anterior (n=78; 89.7%), unilateral (n=72; 82.8%), acute (n=19; 82.6%), and non-recurrent (n=83; 95.4%).The comparative study between these three groups of SpAs showed a significant greater frequency of HLA-B27 positive, anterior location and acute onset in ax-SpA-related uveitis (Table 1).Table 1.Main clinical features and uveitis pattern.Ax-SpA (n=44)PsA (n=20)IBD (n=23)pMain general featuresAge, years, mean ±SD45.6 ± 10.343.1 ± 14.549.1 ± 14.60.472Sex, w/m, n, (% of women)25/19 (56.8)12/8 (60)17/6 (73.9)0.382Disease Duration, years, mean±SD18.6 ± 10.59.9 ± 8.217.4 ± 10.20.067HLA-B27 positive, n (%)37 (84.1)9 (45)5 (2.8)0.001*Uveitis locationAnterior, n (%)44 (100)16 (80)18 (78.3)0.006*Posterior, n (%)0 (0)0 (0)4 (17.4)-Panuveitis, n (%)0 (0)0 (0)1 (4.5)-Uveitis patternUnilateral, n (%)37 (84.1)16 (80)19 (82.6)0.922Uveitis onsetAcute, n (%)44 (100)20 (100)19 (82.6)0.003*ConclusionAlthough SpAs associated uveitis have different frequencies depending on the underlying disease, they share the same clinical pattern: anterior, unilateral, acute, and non-recurrent, in contrast with published data from selected series.References[1]Paiva ES, et al. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis. 2000; 59:67-70.[2]Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol. 1997;115:61-4.Disclosure of InterestsNone declared

Background:Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD), and Ulcerative colitis (UC) are related to Spondyloarthritis (SpA). Ocular manifestations (OM) are well-stablished in axial SpA but not in IBD. It has been classically reported that whereas uveitis with axial SpA is predominantly anterior, unilateral, acute, and non-recurrent; in IBD it is bilateral, posterior, insidious, and chronic (1).Objectives:In a large unselected series of IBD, our aim was to assess a) epidemiology and clinical features of uveitis associated to IBD, b) to compare patients who developed uveitis and those who did not, and c) its relationship with biological treatment used in IBD.Methods:Study of all consecutive patients from a single University Hospital during the last 40 years with: a) IBD (CD and UC), and b) uveitis according to Standarization Uveitis Nomenclature (SUN) Working Group. Demographic features, clinical findings, occurrence of other extraintestinal manifestations and treatment were recorded.Results:We studied 1449 (714 women/735 men) patients with IBD, mean age of 55.2±15.9 years.Uveitis was present in 23 (1.6 %) (38 eyes) of 1448 IBD patients. The most common pattern of uveitis was typically anterior (n=18; 78.3%), unilateral (n=19; 82.6%), acute (n=19; 82.6%), and non-recurrent (n=12; 52.2%).The comparative study between patients with and without uveitis showed a significant predominance of women (Table 1) in patients with uveitis, as well as erythema nodosum, hidradenitis suppurativa and joint involvement.Regarding IBD severity, in terms of surgical interventions, and conventional and biological immunosuppressive treatments, there were no significant differences.Conclusion:Although uveitis is more infrequent in IBD than in axial SpA, it is also anterior, unilateral, acute, and non-recurrent in contrast with published data from selected series. Patients with uveitis do not seem to represent more severe phenotype of IBD.References:[1]Lyons & Rosenbaum JT. Arch Ophthalmol 1997; 115:61-4.Table 1.General features of 1448 patients with IBD with and without uveitis.Overall(n=1449)Uveitis(n=23)Non uveitis(n=1426)pMain general featuresAge, years, mean±SD55.2±15.949.1±14.655.2±15.90.8Sex, women/men, n, (% of women)714 / 735 (49.3)17 / 6 (73.9)697 / 729 (48.9)0.02*IBD duration, years, mean±SD13.2 ± 9.717.4 ± 10.213.1 ± 8.90.08IBD SeveritySurgical Interventions, n (%)289 (19.9)2 (8.7)284 (19.9)0.7Conventional Immunosuppressive drugs, n (%)878 (60.6)14 (60.9)863 (60.5)0.5Biological Therapy, n (%)384 (26.5)7 (30.4)378 (26.5))0.9TNFi monoclonal antibodies384 (26.5)7 (30.4)378 (26.5)0.9Ustekinumab27 (1.9)1 (4.3)27 (1.9)0.5Other23 (1.6)1 (4.3)22 (1.6)0.3Extraintestinal manifestationsCutaneous manifestations, n (%) (TOTAL)125 (8.6)9 (39.1)121 (8.7)0.1Erythema nodosum, n (%)26 (1.8)6 (26.1)24 (1.7)0.009*Pyoderma gangrenosum, n (%)13 (0.9)1 (4.3)13 (0.9)0.7Hidradenitis suppurativa, n (%)2 (0.1)1 (4.3)1 (0.1)0.0001*Joint involvement, n (%) (TOTAL)131 (9)10 (43.5)121 (8.5)0.0001*Axial pattern, n (%)65 (4.5)4 (17.4)58 (4.1)0.0001*Peripheral pattern, n (%)64 (4.4)4 (17.4)63 (4.4)0.9Disclosure of Interests:Lara Sanchez-Bilbao: None declared, María José García-García: None declared, David Martínez-López: None declared, Montserrat Rivero-Tirado: None declared, Beatriz Castro: None declared, Iñigo González-Mazón: None declared, Javier Crespo: None declared, Miguel A González-Gay Speakers bureau: AbbVie, Pfizer, Roche, Sanofi, Celgene and MSD., Grant/research support from: AbbVie, MSD, Jansen and Roche,, Ricardo Blanco Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD., Grant/research support from: AbbVie, MSD and Roche